Buy reliable Quality Eptifibatide 188627-80-7 raw material with Honest Price
- Molecular Formula:C35H49N11O9S2
- Molecular Weight:831.974
- Appearance/Colour:White powder
- Refractive Index:1.742
- PKA:4.01±0.10(Predicted)
- PSA：374.49000
- Density:1.605 g/cm3
- LogP:1.62840
Eptifibatide(Cas 188627-80-7) Usage
|
Biological Activity
|
Eptifibatide, also known as Integrilin, is a natural disintegrin found in snake venom that has biological activity as an antiplatelet drug: Binds to Gp IIb/IIIa receptor, Inhibits platelet aggregation and Other uses. |
|
Mechanism of action
|
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that prevents platelet aggregation by binding to the KGD binding sites on the GP IIb/IIIa receptor on human platelets. This binding prevents fibrinogen, von Willebrand factor, and other adhesive ligands from binding to the receptor, which reversibly inhibits platelet aggregation. |
|
Drug interactions
|
Potentially hazardous interactions with other drugs Iloprost: increased risk of bleeding.
|
|
Metabolism
|
Eptifibatide is not known to be metabolized by cytochrome P450 but is deaminated by metabolic enzymes. |
|
Definition
|
Eptifibatide is a synthetic peptide that prevents platelets from aggregating by blocking the glycoprotein IIb/IIIa receptor on platelets. It's a reversible, cyclic heptapeptide that's derived from a protein found in the venom of the southeastern pygmy rattlesnake. |
|
Brand name
|
Integrilin
|
|
Uses
|
Eptifibatide is effective in reducing ischemic complications of patients undergoing elective PCI. Shanghai Wibson Biotechnology Co., Ltd. is a high-tech enterprise that mainly develops and sells pharmaceutical and chemical raw materials and other related products. The company has advanced and perfect supporting system and has formed advanced chemical synthesis technology, which can quickly meet the personalized needs and series development from suitable testing to industrial production. Products are exported to Russia, Southeast Asia and other countries, in the world has a very high reputation and visibility. The company has strong financial strength and a good operating environment, can provide customers with high-quality, efficient and fast services. |
InChI:InChI=1/C35H49N11O9S2/c36-31(52)26-17-57-56-12-10-27(47)43-22(7-3-4-11-39-35(37)38)32(53)41-16-28(48)44-25(14-29(49)50)34(55)45-24(13-18-15-40-20-6-2-1-5-19(18)20)30(51)21-8-9-23(42-21)33(54)46-26/h1-2,5-6,15,21-26,40,42H,3-4,7-14,16-17H2,(H2,36,52)(H,41,53)(H,43,47)(H,44,48)(H,45,55)(H,46,54)(H,49,50)(H4,37,38,39)/t21?,22-,23-,24-,25-,26-/m0/s1
188627-80-7 Relevant articles
A Review of Clinical Trials with Eptifibatide in Cardiology
Uwe Zeymer, Harm Wienbergen
Cardiovascular Drug Reviews, 15 November 2007
In patients with STEMI eptifibatide has been studied as an adjunct to fibrinolysis and primary PCI; it improved epicardial flow and tissue reperfusion. Current studies are evaluating eptifibatide as upstream therapy in high-risk patients with NSTE-ACS, in the EARLY-ACS and in comparison with abciximab in patients with primary PCI in the EVA-AMI trial.
Long-term Efficacy of Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention
J. Conor O'Shea, MD; Christopher E. Buller, MD; Warren J. Cantor, MD
JAMA. 2002;287(5):618-621.
Complete follow-up data were available for 988 patients given eptifibatide (95.0%) and 976 patients given placebo (95.3%). By 12 months, the composite of death or MI had occurred in 8.0% of eptifibatide-treated patients and in 12.4% of placebo-treated patients (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.48-0.83; P = .001).
188627-80-7 Upstream products
188627-80-7 Downstream products
-
1248559-53-6
eptifibatide acetate
English
中文
